Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Cutaneous malacoplakia in heart transplanted patient].
Rémond B, Dompmartin A, De Pontville M, Moreau A, Mandard JC, Leroy D. Rémond B, et al. Among authors: de pontville m. Ann Dermatol Venereol. 1993;120(11):805-8. Ann Dermatol Venereol. 1993. PMID: 8210124 Review. French. No abstract available.
[Psoriatic onycho-pachydermo-periostitis].
De Pontville M, Dompmartin A, De Raucourt S, Macro M, Rémond B, Leroy D. De Pontville M, et al. Ann Dermatol Venereol. 1993;120(3):229-32. Ann Dermatol Venereol. 1993. PMID: 8239363 French.
Assessing immune organs on 18F-FDG PET/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients.
Prigent K, Lasnon C, Ezine E, Janson M, Coudrais N, Joly E, Césaire L, Stefan A, Depontville M, Aide N. Prigent K, et al. Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2573-2585. doi: 10.1007/s00259-020-05103-3. Epub 2021 Jan 12. Eur J Nucl Med Mol Imaging. 2021. PMID: 33432374
18F-FDG PET/CT versus Diagnostic Contrast-Enhanced CT for Follow-Up of Stage IV Melanoma Patients Treated by Immune Checkpoint Inhibitors: Frequency and Management of Discordances over a 3-Year Period in a University Hospital.
Le Goubey JB, Lasnon C, Nakouri I, Césaire L, de Pontville M, Nganoa C, Kottler D, Aide N. Le Goubey JB, et al. Among authors: de pontville m. Diagnostics (Basel). 2021 Jul 1;11(7):1198. doi: 10.3390/diagnostics11071198. Diagnostics (Basel). 2021. PMID: 34359281 Free PMC article.
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study.
Mortier L, Villabona L, Lawrence B, Arance A, Butler MO, Beylot-Barry M, Saiag P, Samimi M, Ascierto PA, Spada F, De Pontville M, Maio M, Berrocal A, Espinosa E, Capdevila J, Levin M, Das D, Krepler C, Grebennik D, Chiarion-Sileni V. Mortier L, et al. Among authors: de pontville m. Am J Clin Dermatol. 2024 Nov;25(6):987-996. doi: 10.1007/s40257-024-00885-w. Epub 2024 Oct 8. Am J Clin Dermatol. 2024. PMID: 39377880 Free PMC article. Clinical Trial.
Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial.
Véron M, Chevret S, Grob JJ, Beylot-Barry M, Saiag P, Fléchon A, You B, Maubec E, Jouary T, Toulemonde E, Jamme P, Gambotti L, Lamrani-Ghaouti A, Dupuy A, Lebbe C, Seguin NB, Houede N, Leccia MT, Le Du F, de Pontville M, Gaudy-Marquestre C, Guillot B, Simon C, Marabelle A, Mortier L. Véron M, et al. Among authors: de pontville m. Eur J Cancer. 2022 Dec;177:103-111. doi: 10.1016/j.ejca.2022.09.013. Epub 2022 Oct 11. Eur J Cancer. 2022. PMID: 36335780 Clinical Trial.
23 results